Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$11.21
--
Market closed
$11.21
--
Day’s Range― - ―
52-Week Range$9.10 - $40.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$592.43M
Enterprise Value$1.33K
Total Cash (Recent Filing)$304.73M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,848,210
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.91Price Target Upside157.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2 Schizophrenia DataThe successful ZEPHYR readout provides clinical validation for ML-007C-MA and supports advancement into registrational Phase 3 development. Efficacy, cognitive signals and tolerability could strengthen the asset’s differentiation if replicated in larger studies.
Funding Runway Through 2028New institutional financing materially improves visibility for funding the VISTA and ZEPHYR-2 programs through important clinical milestones. A longer runway can reduce near-term execution disruption and support focused investment in the lead asset.
Strong Balance SheetVery low leverage and substantial equity provide financial flexibility unusual for a development-stage biotech. This capitalization gives MapLight more capacity to fund clinical programs and absorb operating volatility while pursuing potential commercialization.
Bears Say
Pre-revenue And Widening LossesMapLight has no commercial revenue to offset its expanding research and operating base, leaving profitability dependent on future clinical success. The sharp increase in annual losses indicates limited operating leverage and continued reliance on external capital.
Accelerating Cash BurnHigher operating and free-cash-flow deficits increase the resources required to reach regulatory milestones. Even with recent financing, sustained burn could require additional equity or other funding, creating longer-term dilution and execution risk.
Pipeline Concentration And Trial RiskThe autism setback narrows near-term pipeline breadth, while pausing earlier programs increases dependence on ML-007C-MA. Any failure in Phase 3 schizophrenia or Phase 2 Alzheimer’s disease psychosis could therefore have an outsized impact.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $9.10 and its highest was $40.43 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $592.43M.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 52,848,210 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.91 (157.89% Upside)
$28.91 (157.89% Upside)
Blogger Sentiment
Neutral
MPLT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 248.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $65.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
337.90%
Trailing 12-Months
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$28.91
▲(157.89% Upside)
Ownership Overview
65.24% Insiders
7.59% Mutual Funds
9.83% Other Institutional Investors
12.37% Public Companies and
Individual Investors